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Abstract Rat aseites hepatoma cells (MM1 cells) penetrate 
through a cultured mesothelial cell monolayer (MCL) in the pres- 
ence of fetal calf serum (FCS), but scarcely do so in its absence. 
Inactivation of rhop21 of MM1 cells by ADP-ribosyltransferase 
C3 resulted in the suppression of this serum effect on the penetra- 
tion, suggesting that the serum effect was mediated by rhop21. 
To ascertain this assumption MM1 cells were transfected with 
an activated (Vai 14) human rhoA cDNA (Neo/RhoA 1-7). The 
transfectants penetrated MCL extensively even in the absence of 
FCS and became largely independent of serum for the penetra- 
tion. These results suggest hat serum-induced invasion by MM1 
cells is mainly mediated by rhop21. 
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1. Introduction 
Metastasis develops by a series of complex sequence of steps, 
among which transcellular migration of tumor cells through the 
host cell layer is most characteristic. The molecular mechanism 
of transcellular migration, however, is still largely unknown. 
We have developed a cell-monolayer invasion assay [1], in 
which tumor cells were seeded on a cultured monolayer of rat 
mesothelial cells (MCL) [1-4]. By counting the number of 
tumor cells that penetrated MCL, we quantified transcellular 
migration of tumor cells (in vitro invasive ability). The in vitro 
invasive ability of tumor cells corresponded well with their 
invasive capacity against he peritoneum, when the cells were 
implanted in the peritoneal cavity of the syngenic rats [5]. 
MM 1 cells (a highly invasive clone from AH 130 cells) pene- 
trated MCL extensively in the presence of serum in the invasion 
assay medium, while in its absence, they scarcely penetrated 
MCL [2]. The addition of l-oleoyl ysophosphatidic a id (LPA) 
into the medium was completely substituted for this serum 
effect, while LPA had no effect on the growth of MM 1 cells [4]. 
Serum- or LPA-activity on inducing the tumor cell invasion was 
not specific to MM1 cells. The invasion of MCL by human 
pulmonary lung cancer (OC10) cells or mouse melanoma 
(B16FE7) cells also significantly depend on the presence of 
serum or LPA in the assay medium [4, unpublished result[. LPA 
is known to stimulate a number of signalling pathways under 
regulation of a small GTP-binding protein rhop21 [6,7,8], These 
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signallings appear to evoke a variety of its biological actions 
such as platelet activation, induction of morphological changes 
of neuronal cells, and proliferation of fibroblasts [7]. Recently, 
Takaishi et al. reported that microinjection of rho GDI, which 
inhibits rhop21 activity, into Swiss 3T3 cells results in suppres- 
sion of cell motility, suggesting the participation of the activa- 
tion of rhop21 in the motility of fibroblasts [9]. In their study 
the cell motility was examined using gold colloid traction assay, 
a measurement for phagokinetic behavior of cells. However, 
the molecular mechanism of transcellular migration of tumor 
cells through host cell monolayers remains largely unknown. 
Taking advantage of our cell monolayer invasion model, we 
have tried to define the involvement of rhop21 in serum-de- 
pendent transcellular migration of MMl cells. In this paper, we 
report that C3, which is known to selectively ADP-ribosylate 
rhop21, strongly suppresses the invasion by MM1 cells, and 
that MM1 cells transfected with Va114 rhoA cDNA, a point- 
mutated active form of rhoA, penetrate MCL extensively in the 
absence of serum. The transfectants became largely independ- 
ent of serum for transcellular migration, suggesting that the 
serum effect is largely mediated by rhop21 which is essentially 
involved in the invasion by MM1 cells. 
2. Materials and methods 
2.1. Materials 
Exoenzyme C3 of Clostridium botulinum (C3) was kindly supplied by 
Dr. B. Syuto (Hokkaido University, Sapporo, Japan) [10]. Purified 
rhoA was a generous gift from Dr. Y. Takai (Osaka University, Osaka, 
Japan). Activated (Val TM) human rhoA cDNA which has a myc epitope 
tag at the N-terminus [11] was kindly supplied by Dr. A. Hall (Institute 
of Cancer Research, London, UK). [32p]NAD was purchased from 
Amersham. 
2.2. Cells and cell culture 
Rat mesothelial cells were isolated from Donryu rat mesentery and 
cultured in modified MEM containing 2-fold amino acid and vitamins 
(Nissui Pharmaceutical Co., Ltd.) supplemented with 10% FCS, as 
reported previously [1 5]. MM1 cells which were cloned from cultured 
AHI30 cells were maintained in modified MEM supplemented with 
10% FCS. 
2.3. Cell-monolayer invasion assay 
The assay procedure of in vitro invasive capacity of tumor cells was 
described in our previous reports [1 5]. Briefly, when mesothelial cells 
t¥om rat mesentery had grown to confluency, the culture medium was 
removed and 2 x 105 MM 1 cells in 2 ml MEM with or without 10% FCS 
were seeded on MCL. After 20 h, the medium was removed and the cells 
were fixed with 10% formalin. The number of penetrated single tumor 
cells and tumor cell colonies (invasion loci) was counted under a phase 
contrast microscope. 
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2.4. ADP-ribosylation by C3 
MM1 cells were treated with predetermined concentrations of C3 
(10pg/ml) in the culture medium supplemented with 10% FCS for 4 h 
followed by washing with MEM. To make sure that the cellular hop21 
was ADP-ribosylated, the amount of unribosylated rhop21 in the ly- 
sates of C3 pretreated cells was determined as described previously [12]. 
Briefly, the lysates of cells that had been treated with C3 were incubated 
in 0.1 ml of 100 mM Hepes/NaOH at pH 7.5 containing 10 mM DTT, 
0.1 mM MgCl2, I0 mM [32p]NAD and 1/.tg C3 at 30°C. After 20-min 
incubation, the reaction was terminated by adding 12 gl of 100% (w/v) 
trichloroacetic a id. Resultant precipitates were dissolved in 40/tl of 
62 mM Tris-HC1 (pH 6.7) containing 3% SDS, 5% 2-mercaptoethanol, 
5% glycerol and 0.001% Bromophenol blue to subject o SDS-PAGE 
(12% polyacrylamide g l). The gel was dried and autoradiographed at 
-80°C on a HyperfilmTM-MP (Amersham). The amount of C3 used 
in Table 2 was more than 5 times larger than those in Table 1. This is 
only because of the difference of the specific activity of C3 in each 
preparation of the enzyme. 
2.5. Transfection 
The pRC/CMV-RhoA plasmid that encodes the activated (VaP 4) 
human rhoA cDNA was subcloned into the drug-selectable pRC/CMV 
vector (Invitrogen). MM1 cells (1 × 10 7 cells/ml) were transfected with 
the pRC/CMV-RhoA plasmid (60 gg/ml) by electroporation using a 
Bio-Rad Gene Pulser. Electroporation conditions were as follows: ca- 
pacitance 25 ktF, field strength 2.5 kV/cm. After the transfection, the 
cells were grown for 48 h, followed by selection with G418 (120,u/ml). 
Seven clonal transfectants were isolated from the resistant cells by 
limiting dilution (Neo/RhoA 1 7). Neo/only transfectant was obtained 
from MM1 ceils transfected with the pRC/CMV plasmid (Neo/only). 
2.6. Reverse transcriptase-polymerase chain reaction (RT-PCR) 
RT-PCR of the Val~4rhoA mRNAs was carried out as follows. The 
first strand cDNA was synthesized from 2.5/.tg of total RNA using 
Moloney Murine Leukemia Virus (M-MuLV) reverse transcriptase and 
oligo (dTh8 primer (Pharmacia Bio.) under incubation at 37°C for 1 h. 
The polymerase chain reaction (PCR) was conducted by the addition 
of 35 pl or PCR reaction mixture containing 50 pmol of sense primer 
(myc epitope tag): 5'-AAGCTGATCTCCGAGGAGGA-Y, 50 pmol 
of antisense primer (nucleotide position of human rhoA 568-587): 5'- 
TCTTCAGGTTTCACCGGCTC-3' and 2.5 units of TaKaRa Ex Taq 
DNA polymerase (TaKaRa Biomedicals) with 30 thermal cycles, 94°C 
for 30 s, 60°C for 2 min, 72°C for 1 min 30 s. A sequence in the neo 
gene was amplified by PCR using a primer set: sense (nucleotide posi- 
tion 750-770) 5'-CAAGATGGATTGCACGCAGGT-Y and antisense 
(nucleotide position 1308-1328) 5'-GATATTCGGCAAGCAGGC- 
ATC-Y. The PCR products were electrophoresed on 3% agaroseX gel 
(Wako Pure Chemical Industries) and stained with ethidium bromide. 
3. Results 
3.1. Diminished invasion by MM1 cells pretreated with C3 
To test whether the invasion by MMI  cells is mediated by 
rhop21, we examined the effects of pretreating MM1 cells by 
C3 on their transcellular migration. C3 is known to selectively 
ADP-ribosylate and inactivate rhop21. MM1 cells were prein- 
Table 1 
Effect of C3 on in vitro invasion by MM1 cells 
C3 ~g/ml) Number of invasion foci/cm ~ 
None 2100 _+ 185 j
0.5 995 + 88 
l 918 ___ 81 
3 613 + 54 
10 229 ± 21 
1 Mean + S.D. of at least 2 determinations. 
MM1 cells (1 x 105/ml) were preincubated with indicated concentra- 
tions of C3 in the culture medium supplemented with 10% FCS for 4 
h. After washed, 2 × 105 MM1 cells in 2 ml MEM supplemented with 
10% FCS were seeded on MCL. 
kDa 
30 
22 
1 2 3 
Fig. 1. ADP-ribosylation of rho protein by C3. Purified rhoA and 
cell lysates of MM1 cells were subjected to ADP-ribosylated by C3 
(10gg/ml) in the presence of [32p]NAD. The labeled proteins were 
analyzed by SDS-PAGE and autoradiography. Lane I: purified rhoA; 
lane 2:MM1 cells pretreated without C3; lane 3:MM1 cells pretreated 
with C3 (10 #g/ml). 
cubated with 0-i0/,tg/ml of C3 for 4 h, washed and then their 
invasive ability was measured by the cell-monolayer invasion 
assay. The transcellular migration of MM 1 cells was inhibited 
by the pretreatment with C3 in the dose-dependent manner 
(Table 1). The inhibition of the migration was almost 90%, 
when the cells were treated with 10 gg/ml of C3 for 4 h. This 
treatment of C3 hardly affected the growth of MM 1 cells during 
the period of invasion assay (data not shown). To confirm that 
rhop21 in MM1 cells was actually ADP-ribosylated by the 
addition of C3 into the culture medium, the amount of ADP- 
ribosylated rhop21 in the lysates of treated MM1 cells was 
determined by examining the incorporation of [32p]ADP into 
residual rhop21 by adding C3 to the lysate. Incorporation of 
[32p]ADP into 22 kDa band corresponding to rhoA p21 was 
found to be reduced in the lysate of treated cells compared with 
the untreated control (Fig. 1), indicating ADP-ribosylation of 
rhop21 by C3 added extracellularly. 
3.2. Val14rhoA expression in transfected cell clones 
To confirm the participation of rhop21 in transcellular mi- 
gration, MM1 cells were transfected with the pRC/CMV- 
Val~4RhoA plasmid. Seven independent clones (Neo/RhoA 
1 7) were isolated and characterized. RT-PCR using the 
ValI4rhoA specific primers spanning over a DNA fragment of 
452 bp indicated that VallarhoA mRNA was expressed in all 
Table 2 
In vitro invasion by Vall4rhoA transfectants 
Cell Number of invasion foci/cm 2
FCS (-) FCS (+) 
MM1 38 + 211 2427 + 102 
Neo/only 43 + 16 2618 ± 64 
Neo/RhoA-1 859 _+ 107 4335 ± 126 
Neo/RhoA-2 360 + 76 3975 ± 149 
Neo/RhoA-3 1007 ± 53 4007 ± 269 
Neo/RhoA-4 3211 + 330 4791 + 252 
Neo/RhoA-5 922 + 144 5226 ± 217 
Neo/RhoA-6 3541 + 176 4887 ± 292 
Neo/RhoA-7 392 + 79 4929 ± 530 
Neo/RhoA-3 
pretreated with C3" ND 2 201 _+ 14 
Mean + S.D. of at least 2 determinations. 
2 Not done. 
MM1 cells (2 × 105/dish) were seeded on MCL in the presence or ab- 
sence of FCS in the assay medium. 
*Neo/RhoA-3 cells (1 × 105/ml) were preincubated with 50 gg/ml of C3 
for 24 h. After washed, 2 × l0 s cells were seeded on MCL in the pres- 
ence of FCS in the assay medium. 
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Fig. 2. Detection of Vall4rhoA mRNA and neo mRNA by RT-PCR. 
Vall4rhoA and neo specific primers were prepared as described in 
section 2. 452 bp and 579 bp bands corresponding to Val~4rhoA and 
neo, respectively, are indicated by arrows. PCR products were electro- 
phoresed on 3% agaroseX gel and detected by ethidium bromide 
staining. 
of these Neo/RhoA clones, but not in parental MM1 cells or 
Neo/only (Fig. 2). Neo mRNA was expressed in both Neo/ 
RhoA clones and Neo/only (Fig. 2). 
3.3. In vitro invasive ability and morphology of VJ4RhoA 
transfectan ts 
Transcellular migration of Val'arhoA transfectants were ex- 
amined by the cell-monolayer invasion assay. As shown in 
Table 2, all of the Neo/RhoA clones invaded extensively in the 
absence of FCS in the assay medium, although the parental 
MM1 cell and Neo/only scarcely invaded. In the presence of 
FCS, however, all the cell lines were highly invasive. Thus the 
serum dependency of MM1 cell invasion was greatly reduced 
by the transfection of Val14rhoA cDNA (Table 2). 
In contrast to parental MM 1 cells and Neo/only which grew 
in suspension, Neo/RhoA clones adhered to culture dishes with 
a scattered morphology (Fig. 3A,B,C). 
To ascertain whether the transfected Val'4rhoA does func- 
tion in the transfectants or not, Neo/RhoA-3 was treated with 
50/lg/ml of C3 for 24 h. The treated cells completely rounded 
up and the cell morphology appeared to be reversed to that of 
the original MM1 cells or Neo/only (Fig. 3D). The invasive 
ability of the C3-treated Neo/RhoA-3 was found to be greatly 
reduced (Table 2). 
4. Discussion 
In this paper, C3, which specifically inactivated rhop21, was 
shown to inhibit the transcellular migration of MM1 cells 
through MCL. Introduction of C3 into fibroblasts uch as 
Swiss 3T3 cells is reported to result in disappearance of stress 
fibers and focal contacts [13]. Therefore, the inhibition of the 
migration of MM 1 cells by C3 may be mediated by the destruc- 
tion of these intracellular structures. This assumption is sup- 
ported by our previous result that cytochalasin B, which dis- 
rupts actin filaments [14[, strongly suppressed the transcellular 
migration of MM 1 cells [15] and our recent finding that serum- 
or LPA-induced F-actin increase in MM1 cells was completely 
suppressed by prior treatment with C3 (unpublished result). C3 
is reported to inhibit spontaneous and chemoattractant-in- 
duced motility of neutrophils [16] and phagokinesis of Swiss 
3T3 cells tested by gold colloid traction assay, as well [9]. Taken 
together, hop21 appears to participate in cell locomotion like 
the transcellular migration as well as in cell motility. 
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We have already found that MM1 cells require the presence 
of FCS in the culture medium to exert heir transcellular migra- 
tion [2], and that LPA can be substituted for the serum [4]. 
Serum or LPA is reported to induce in fibroblasts the rapid 
formation of actin stress fibers and the assembly of focal adhe- 
sion plaques through rhop21 pathway [8,13]. These observa- 
tions and the above results with C3 lead to speculate that the 
migration-inducing effect of FCS is mediated by rhop21 activa- 
tion. To test this possibility, we introduced human Val14rhoA 
cDNA, a constitutively active form of rhoAp21, into MM 1 cells 
and tested whether the transfectants migrate through MCL 
even in the absence of FCS. As a result, the transfectants ex- 
erted extensive transcellular migration without adding FCS in 
the assay medium (Table 2). Furthermore, they became mostly 
independent of serum for the migration, suggesting that FCS 
triggers the migration by signalling largely through rhop21 
activation. 
During the preparation of this manuscript, Michiels et al. 
reported using a similar invasion model to ours that the intro- 
duction of active rac (a small G protein in the rho subfamily) 
conferred to non-invasive lymphoma BW5147 cells an ability 
to migrate through a fibroblast monolayer [17]. As described, 
rhop21 essentially contributes to the migration of MM1 cells 
through MCL. Additionally, we observed that suppression of 
the migration of tumor cells by knocking out rhop21 activity 
using C3 was not specific to MM1 cells but was seen with the 
other tumor cells ([4], unpublished result). The reason for the 
preferential participation ofrac or rho in different experimental 
systems is not clear at present. The small G protein necessary 
for the transcellular migration of tumor cells might be different 
depending on the pair of tumor and host cells. Alternatively, 
the activation of both rac and rho may be necessary for tumor 
cells to locomote, as suggested that cdc42-rac-rho sequence 
may function in cell locomotion [18,19]. The rac activation 
system leading to induction of transcellular migration might be 
~._ 
Fig. 3. Morphology of Val14rhoA transfectant. (A) MM1 cells. 
(B) Neo/only cells. (C) Neo/RhoA-3 cells. (D) C3 treated Neo/RhoA-3 
cells. 
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deficient in lymphoma cells, whereas the rho activation system 
is silent in MM1 cells in the absence of serum. In Michiels' 
experiment, BW5147 cells were non-invasive in the presence of 
serum in the assay medium. It is interesting to see whether 
BW5147 cells and active rac-transfectants migrate through the 
fibroblast monolayer even in the absence of serum or not. This 
may give a better understanding of the relation between rac and 
rho. Although further investigation will be required, our results 
presented here will give critical information to understand the 
signalling of transcellular migration of tumor cells. 
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